Eli Lilly and Co. (NYSE:LLY) is phasing out select insulin products across parts of Europe for commercial reasons, with regulators emphasizing that the move is not linked to safety or quality concerns.
The withdrawals, which vary by country, are expected to be completed before the second quarter of 2027.
Select Insulin Products To Be Withdrawn By 2027
The company confirmed it will discontinue certain insulin presentations containing human insulin, insulin lispro, and insulin glargine across multiple EU and EEA markets.
The specific products impacted — along with the timing of their removal — differ by country.
Separately, Humalog Mix25, a formulation combining insulin lispro and insulin lispro protamine, has already been discontinued in all EU and EEA countries where it was previously marketed.
Decision Driven By Commercial Considerations
Eli Lilly said the decision to halt marketing of these insulin products is based on commercial factors rather than any manufacturing defect or safety-related issue.
The company did not indicate any concerns tied to product efficacy or patient risk.
The impact of the discontinuation will vary across member states, depending on local availability and reliance on specific insulin presentations.
Regulators Monitoring Supply Impact
The Medicines Shortages Single Point of Contact Working Party is coordinating with stakeholders to monitor supply conditions and mitigate potential disruptions.
Health authorities have advised patients and healthcare providers to consult national shortage registers or contact local regulators for the latest updates on insulin availability.
Eli Lilly Retatrutide Shows Strong A1C Reduction And Weight Loss
Retatrutide is an investigational once-weekly triple hormone receptor agonist that activates the body's receptors for glucose-dependent insulinotropic polypeptide (GIP), glucagon-like peptide-1 (GLP-1), and glucagon.
In the latest updates, Eli Lilly announced that retatrutide significantly lowered A1C (blood sugar) levels by an average of 1.7% to 2.0% over 40 weeks in the TRANSCEND-T2D-1 trial.
Participants taking the 12 mg dose also lost an average of 36.6 lbs (16.8%), with no plateau in weight loss observed throughout the trial duration.
LLY Price Activity: Eli Lilly shares were down 0.13% at $909.39 during premarket trading on Tuesday, according to Benzinga Pro data.
Image via Shutterstock